Five things for pharma marketers to know: Thursday, September 1, 2016

1. Novartis said it will fold its cell and gene therapy unit in other business units, but noted that the restructuring will not impact the drugmaker's plans to seek approval for CTL019, a chimeric antigen receptor T cell (CAR-T) therapy, an experimental cancer treatment. (Reuters)

2. Novo Nordisk said CEO Lars Rebien Soerensen will retire at the end of this year and Lars Fruergaard Joergensen, EVP and head of corporate development, has been tapped to replace him. The move is unexpected. (Bloomberg)

3. The FDA issued a safety warning about combining opioid painkillers with certain anti-anxiety drugs. (WSJ)

4. Using mobile apps and web-based programs helps people lose weight and quit smoking — and even more so if a healthcare provider is involved — but researchers say more studies are needed to understand whether these tools are sustainable interventions. (Reuters)

5. An experimental drug, aducanumab, dramatically reduced plaques found in the brains of patients with Alzheimer's disease, according to a study published in Nature. Biogen is developing the drug. (NPR)